¼¼°èÀÇ ½ÉÀåÀ絿±âÈ­ Ä¡·á(CRT) ±â±â ½ÃÀå
Cardiac Resynchronization Therapy (CRT) Devices
»óǰÄÚµå : 1564035
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 194 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÉÀåÀ絿±âÈ­ Ä¡·á(CRT) Àåºñ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 109¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù

2023³â 65¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ±â±â ¼¼°è ½ÃÀåÀº 2030³â 109¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 7.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ CRT-Á¦¼¼µ¿±â(CRT-D)´Â 7.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÏ¿© ºÐ¼® ±â°£ ¸»¿¡ 78¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CRT-½É¹ÚÁ¶À²±â(CRT-P) ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È 8.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 18¾ï ´Þ·¯, Áß±¹Àº CAGR 7.3%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ ½ÉÀåÀ絿±âÈ­Ä¡·á(CRT) ±â±â ½ÃÀåÀº 2023³â 18¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 17¾ï ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 7.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 7.0%¿Í 6.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 7.2%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á(CRT) ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

½ÉÀåÀ絿±âÈ­Ä¡·á(CRT) Àåºñ¶õ ¹«¾ùÀ̸ç, ¿Ö ÇÊ¿äÇѰ¡?

½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ÀåÄ¡´Â ½ÉºÎÀü °ü¸®, ƯÈ÷ ½ÉÀåÀÇ È¿À²ÀûÀÎ ¹Úµ¿ ´É·ÂÀ» ¼Õ»ó½ÃŰ´Â Àü±â Àüµµ Àå¾Ö¸¦ ¾Î°í Àִ ȯÀڵ鿡°Ô Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ÀåÄ¡´Â ½ÉÀåÀÇ ½É½Ç ¼öÃàÀ» ȸº¹Çϰí Àü¹ÝÀûÀÎ ÆßÇÁ È¿À²À» °³¼±Çϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç, ÀϹÝÀûÀ¸·Î ½É¹ÚÁ¶À²±â ¶Ç´Â À̽ÄÇü Á¦¼¼µ¿±â(ICD)·Î ±¸¼ºµÇ¸ç, ½ÉÀåÀÇ ¾ç ½É½Ç¿¡ ¼³Ä¡µÇ´Â ¸®µå¼±ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. CRT ÀåÄ¡´Â ½É½Ç¿¡ µ¿±âÈ­µÈ Àü±â ÆÞ½º¸¦ º¸³» ½ÉºÎÀü ¹× ´Ù¸® Â÷´Ü ȯÀÚ¿¡°Ô¼­ ÈçÈ÷ ³ªÅ¸³ª´Â ½ÉÀå ¹Úµ¿ ºÒ±ÔÄ¢¼ºÀ» ±³Á¤ÇÕ´Ï´Ù. ÀÌ Ä¡·á¹ýÀº Á¾Á¾ Áߵ¿¡¼­ ÁßÁõÀÇ ½ÉºÎÀü ȯÀڵ鿡°Ô ó¹æµÇ¸ç, ±âÁ¸ Ä¡·á¹ýÀÌ È¿°ú°¡ ¾ø´Â ȯÀڵ鿡°Ô ó¹æµÇ¸ç, CRTÀÇ ±Ã±ØÀûÀÎ ¸ñÇ¥´Â È£Èí°ï¶õ, ÇǷΰ¨ µî ½ÉºÎÀü Áõ»óÀ» ÁÙÀÌ°í »îÀÇ ÁúÀ» °³¼±Çϸç ÀÔ¿ø ¹× »ç¸Á À§ÇèÀ» ³·Ãß´Â °ÍÀÔ´Ï´Ù. ½ÉºÎÀüÀº Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÇ »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, CRT ÀåÄ¡´Â ÀÌ ¸¸¼ºÀûÀ̰í Á¾Á¾ ¼è¾àÇØÁö´Â ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ ÀÖ¾î Áß¿äÇÑ °³ÀÔÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

CRT ÀåÄ¡ÀÇ È¿À²¼ºÀ» ³ôÀÌ´Â ±â¼úÀº?

CRT ÀåÄ¡ÀÇ ±â¼úÀû ¹ßÀüÀº ±× È¿°ú, ¾ÈÀü¼º ¹× ȯÀÚÀÇ Àü¹ÝÀûÀÎ °æÇèÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÁÖ¿ä ¹ßÀü Áß Çϳª´Â ȯÀÚÀÇ È°µ¿ ¼öÁذú ½ÉÀå ¸®µë¿¡ µû¶ó ÀÚµ¿À¸·Î ¼Óµµ¸¦ Á¶ÀýÇÏ´Â ÀûÀÀÇü CRT ½Ã½ºÅÛÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº È޽İú ¿îµ¿ µî ´Ù¾çÇÑ Á¶°Ç¿¡¼­ ½ÉÀå ¹Úµ¿À» ÃÖ´ëÇÑ È¿À²ÀûÀ¸·Î ¸¸µé¾î Ä¡·á¸¦ ÃÖÀûÈ­Çϴ ÷´Ü ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ Å« Çõ½ÅÀº ȯÀÚ µ¥ÀÌÅ͸¦ ÀÇ·áÁø¿¡°Ô ½Ç½Ã°£À¸·Î Àü¼ÛÇÒ ¼ö ÀÖ´Â ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀÇ ÅëÇÕÀÔ´Ï´Ù. À̸¦ ÅëÇØ ÀÓ»óÀÇ´Â ÀÚÁÖ ¹æ¹®ÇÏÁö ¾Ê°íµµ ÀåºñÀÇ ¼º´É°ú ȯÀÚÀÇ ½ÉÀå »óŸ¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ø°Ý ¸ð´ÏÅ͸µÀº Àû½Ã¿¡ Ä¡·á¸¦ Á¶Á¤ÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀÔ¿ø ¹× ÀÀ±Þ °³ÀÔÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. ¶ÇÇÑ CRT ÀåºñÀÇ ¼ÒÇüÈ­·Î ÀÎÇØ ħ½ÀÀÌ ÁÙ¾îµé°í ȯÀÚ¿¡°Ô ´õ Æí¾ÈÇÔÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÛ°í È¿À²ÀûÀÎ ÀåÄ¡´Â ¹èÅ͸® ¼ö¸íÀÌ ±æ¾îÁö°í À̽ÄÇϱ⠽¬¿öÁ® ¼ö¼ú Áß ÇÕº´Áõ À§ÇèÀÌ °¨¼ÒÇßÀ¸¸ç, CRT ÀåÄ¡¿¡ ¹«¼± ±â¼úÀÌ Å¾ÀçµÇ¾î ÀåÄ¡¿Í ¿ÜºÎ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ °£ÀÇ ¿øÈ°ÇÑ Åë½ÅÀÌ °¡´ÉÇØÁ® ȯÀÚ Ä¡·á°¡ ´õ¿í Çâ»óµÇ¾ú½À´Ï´Ù. °³¼±µÇ¾ú½À´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ½ÉºÎÀü Ä¡·á¿¡¼­ CRT ÀåÄ¡ÀÇ Á¤È®¼º°ú È¿´ÉÀÌ Çâ»óµÇ¾î ȯÀÚ¿¡°Ô ´õ ³ªÀº Ä¡·á °á°ú¸¦ °¡Á®¿Ã °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÉÀå À絿±âÈ­ Ä¡·á±â±âÀÇ ÁÖ¿ä ½ÃÀå µ¿ÇâÀº?

½ÉÀå À絿±âÈ­ Ä¡·á ±â±â ½ÃÀåÀº ±â¼ú ¹ßÀü, Àα¸ Åë°èÇÐÀû º¯È­, ÀÇ·á ¼­ºñ½º Á¦°øÀÇ º¯È­·Î ÀÎÇØ Çü¼ºµÈ ¸î °¡Áö Áß¿äÇÑ Æ®·»µå¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ µ¿Çâ Áß Çϳª´Â Àü ¼¼°èÀûÀ¸·Î ½ÉºÎÀü À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ´Â Àα¸ °í·ÉÈ­¿Í °íÇ÷¾Ð, ´ç´¢º´, °ü»óµ¿¸ÆÁúȯ µî ½ÉºÎÀü ¹ßº´¿¡ °ü¿©ÇÏ´Â ÁúȯÀÇ ¹ßº´·ü Áõ°¡°¡ ÁÖ¿ä ¿øÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¾à¹° Ä¡·á¸¸À¸·Î´Â È¿°ú¸¦ º¸Áö ¸øÇϴ ȯÀÚµéÀÇ Ä¡·á ¿É¼ÇÀ¸·Î CRT Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¿ä Æ®·»µå´Â ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÇ µðÁöÅÐ Ç÷§ÆûÈ­°¡ ÁøÇàµÇ¸é¼­ ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀ» °®Ãá CRT ±â±âÀÇ º¸±ÞÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. À̴ ȯÀÚ °ü¸®¸¦ Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ¿ø°Ý ÀÇ·á ¹× ÀçÅÃÄ¡·á¸¦ ÁöÇâÇÏ´Â Àü ¼¼°èÀûÀÎ Ãß¼¼¿Íµµ ÀÏÄ¡ÇÕ´Ï´Ù. ¶ÇÇÑ, CRT ±â±âÀÇ ¼ÒÇüÈ­ ¹× ¸®µå ¾ø´Â ¹öÀüÀÌ °³¹ßµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ±â±âÀÇ Àúħ½ÀÈ­ ¹× ¸®µå °ü·Ã ÇÕº´Áõ °¡´É¼ºÀ» °¨¼Ò½ÃÅ´À¸·Î½á ½ÃÀå¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ƯÈ÷ ºÏ¹Ì¿Í À¯·´°ú °°Àº ¼±Áø Áö¿ª¿¡¼­´Â ±ÔÁ¦ ´ç±¹ÀÌ »ý¸í ±¸¸í ±â¼úÀ» ȯÀÚ¿¡°Ô ´õ »¡¸® Àü´ÞÇϱâ À§ÇØ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϸ鼭 ÀÌ·¯ÇÑ Çõ½ÅÀû ±â±â¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ¿©·¯ Áö¿ª¿¡¼­ ÀÇ·á º¸Çè Àû¿ë ¹× »óȯ Á¤Ã¥ÀÌ È®´ëµÊ¿¡ µû¶ó CRT ±â±â°¡ ´õ ¸¹Àº ȯÀڵ鿡°Ô Á¢±Ù¼ºÀÌ ³ô¾ÆÁ® º¸±ÞÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

CRT ±â±â ½ÃÀå È®´ë ¿äÀÎÀº ¹«¾ùÀΰ¡?

½ÉÀå À絿±âÈ­ Ä¡·á ±â±â ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÇコÄÉ¾î Æ®·»µå º¯È­, ȯÀÚÃþÀÇ º¯È­¿Í °ü·ÃµÈ ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº Àü ¼¼°èÀûÀ¸·Î ½ÉºÎÀü À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ °í·ÉÈ­°¡ ÁøÇàµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ½ÉºÎÀü ȯÀÚ ¼ö°¡ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó CRT¿Í °°Àº È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ±âÁ¸ ½ÉºÎÀü Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀڵ鿡°Ô ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ÀûÀÀÇü CRT ±â±âÀÇ °³¹ß ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀÇ ÅëÇÕ µî CRT ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ±â±âÀÇ ¸Å·ÂÀº ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ °íÀ¯ÇÑ ¿ä±¸¿¡ µû¶ó ÆäÀÌ½Ì ¸Å°³º¯¼ö¸¦ ÀÚµ¿À¸·Î Á¶Á¤ÇÏ´Â ÀûÀÀÇü ½Ã½ºÅÛÀº Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۰í ÇÕº´Áõ ¹ß»ý °¡´É¼ºÀ» °¨¼Ò½Ãŵ´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ È®»êÀ¸·Î µ¥ÀÌÅ͸¦ ¿øÈ°ÇÏ°Ô Àü¼ÛÇÒ ¼ö ÀÖ´Â CRT ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÉºÎÀü ȯÀÚ¸¦ º¸´Ù Àû±ØÀûÀ̰í È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, Äڷγª19 »çÅ·ΠÀÎÇØ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ´Â ÀçÅÃÄ¡·á·ÎÀÇ ÀüȯÀº ¸¸¼º Áúȯ °ü¸®¿¡¼­ ¿ø°Ý ¸ð´ÏÅ͸µÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¸ð´ÏÅ͸µÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀçÀÔ¿ø °¨¼Ò¿Í Àå±â ¿¹ÈÄ °³¼±¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀÇ·á ½Ã½ºÅÛÀÌ °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨À» äÅÃÇÏ°Ô µÈ °Íµµ ¶Ç ´Ù¸¥ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÉÀå ±â´ÉÀ» °³¼±Çϰí ÀÀ±Þ °³ÀÔÀÇ Çʿ伺À» ÁÙ¿©ÁÖ´Â CRT´Â ÀÌ·¯ÇÑ ÀÇ·á ¸ñÇ¥¿¡ ºÎÇÕÇÕ´Ï´Ù. ¶ÇÇÑ, CRT ±â±âÀÇ ¼ÒÇüÈ­¿Í ¹èÅ͸® ¼ö¸í Çâ»óÀ¸·Î ÀÎÇØ CRT ±â±âÀÇ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í, ħ½À¼ºÀÌ ³·¾ÆÁö°í, ³»±¸¼ºÀÌ Çâ»óµÇ¾î ȯÀÚ ¸¸Á·µµ°¡ ³ô¾ÆÁ® Àü¹ÝÀûÀÎ º¸±Þ·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ À¯¸®ÇÑ ±ÔÁ¦ Á¤Ã¥°ú ÀÇ·á º¸ÇèÀÇ È®´ë´Â ȯÀÚÀÇ »ý¸í À¯Áö Àåºñ¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(42°³»ç)

  • Abbott Cardiovascular
  • Biotronik SE & Co.
  • Boston Scientific Corporation
  • EBR Systems, Inc.
  • Lepu Medical Technology£¨Beijing£©Co.
  • LivaNova PLC
  • Medico SpA
  • Medtronic Plc
  • MicroPort Scientific Corporation
  • Osypka Medical GmbH

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cardiac Resynchronization Therapy (CRT) Devices Market to Reach US$10.9 Billion by 2030

The global market for Cardiac Resynchronization Therapy (CRT) Devices estimated at US$6.5 Billion in the year 2023, is expected to reach US$10.9 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. CRT-Defibrillator (CRT-D), one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$7.8 Billion by the end of the analysis period. Growth in the CRT-Pacemaker (CRT-P) segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 7.3% CAGR

The Cardiac Resynchronization Therapy (CRT) Devices market in the U.S. is estimated at US$1.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Cardiac Resynchronization Therapy (CRT) Devices Market - Key Trends and Drivers Summarized

What Are Cardiac Resynchronization Therapy (CRT) Devices and Why Are They Essential?

Cardiac Resynchronization Therapy (CRT) devices are critical tools in the management of heart failure, particularly for patients suffering from electrical conduction problems that impair the heart’s ability to beat efficiently. These devices are designed to restore the coordinated contraction of the heart's ventricles, improving its overall pumping efficiency. CRT devices typically consist of a pacemaker or an implantable cardioverter-defibrillator (ICD) equipped with leads that are placed in both ventricles of the heart. By delivering synchronized electrical pulses to the ventricles, CRT devices correct the misalignment in heartbeats that is common in patients with heart failure or bundle branch block. This form of therapy is often prescribed for individuals who have moderate to severe heart failure and who have not responded well to conventional treatments. The ultimate goal of CRT is to reduce the symptoms of heart failure, such as shortness of breath and fatigue, improve the quality of life, and lower the risk of hospitalization or death. With heart failure affecting millions of people worldwide, CRT devices represent a vital intervention in the management of this chronic and often debilitating condition.

How Is Technology Enhancing the Effectiveness of CRT Devices?

The technological evolution of CRT devices has significantly enhanced their effectiveness, safety, and the overall patient experience. One of the key advancements in this field has been the development of adaptive CRT systems that automatically adjust pacing based on a patient’s activity levels and heart rhythms. These systems utilize sophisticated algorithms to optimize therapy by ensuring the heart beats as efficiently as possible under various conditions, such as rest or exercise. Another major innovation is the integration of remote monitoring capabilities, allowing real-time transmission of patient data to healthcare providers. This enables clinicians to continuously monitor the performance of the device and the patient's heart condition without the need for frequent in-person visits. Remote monitoring not only improves patient outcomes through timely adjustments in therapy but also reduces the need for hospitalizations and emergency interventions. Additionally, the miniaturization of CRT devices has made them less invasive and more comfortable for patients. These smaller, more efficient devices now have longer battery lives and are easier to implant, reducing the risk of complications during surgery. The inclusion of wireless technology in CRT devices has further improved patient care, allowing for seamless communication between the device and external monitoring systems. As technology continues to advance, the precision and efficacy of CRT devices in treating heart failure are expected to grow, offering even better outcomes for patients.

What Are the Key Market Trends in Cardiac Resynchronization Therapy Devices?

Several important trends are driving the cardiac resynchronization therapy devices market, shaped by advancements in technology, demographic shifts, and changes in healthcare delivery. One of the most notable trends is the increasing prevalence of heart failure globally, largely driven by aging populations and the rising incidence of conditions such as hypertension, diabetes, and coronary artery disease, all of which contribute to the onset of heart failure. This has fueled the demand for CRT devices as a treatment option for patients who are not responding to medications alone. Another key trend is the growing adoption of remote patient monitoring solutions. With healthcare systems increasingly moving towards digital platforms, CRT devices with remote monitoring capabilities are becoming more widespread. This not only improves patient management but also aligns with the global trend towards telemedicine and home-based care. Furthermore, the ongoing miniaturization of CRT devices and the development of leadless versions are set to revolutionize the market by making the devices less invasive and reducing the potential for lead-related complications. Regulatory approval of these innovative devices is accelerating, particularly in developed regions like North America and Europe, where regulatory agencies have streamlined processes to get these life-saving technologies to patients faster. Lastly, the expansion of healthcare coverage and reimbursement policies in several regions is making CRT devices more accessible to a broader patient population, driving increased adoption.

What Are the Factors Driving Expansion of the CRT Devices Market?

The growth in the cardiac resynchronization therapy devices market is driven by several key factors tied to advancements in technology, shifts in healthcare trends, and changing patient demographics. A primary driver is the rising prevalence of heart failure across the globe, particularly in aging populations. As the number of heart failure patients continues to increase, so does the demand for effective treatment options like CRT, which is especially critical for patients who do not respond to conventional heart failure therapies. The ongoing advancements in CRT technology, such as the development of adaptive CRT devices and the integration of remote monitoring capabilities, have significantly enhanced the appeal of these devices. Adaptive systems that automatically adjust pacing parameters based on patient-specific needs improve therapy effectiveness and reduce the likelihood of complications. Moreover, the widespread adoption of telemedicine and remote patient monitoring has boosted the demand for CRT devices that can seamlessly transmit data, allowing for more proactive and efficient management of heart failure patients. The shift toward home-based care, further accelerated by the COVID-19 pandemic, has emphasized the importance of remote monitoring in chronic disease management. Another driver is the increasing focus on reducing hospital readmissions and improving long-term outcomes, which has led healthcare systems to embrace value-based care models. CRT devices, by improving heart function and reducing the need for emergency interventions, align well with these healthcare goals. Additionally, advancements in device miniaturization and battery life are making CRT devices more accessible, less invasive, and more durable, leading to higher patient satisfaction and better overall adoption. Finally, favorable regulatory policies and expanding healthcare coverage, especially in developed markets, have made it easier for patients to access these life-saving devices, further fueling market growth.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â